Skip to content

Home
IOncology
Infectious Desease Frontier
IHepatology
Hematology Frontier
Conference topics
Experts Interviews
Informations
Live Broadcasting
Logout

Connecting Medical Expertise through Media

Search for:

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Search for:

#HepatobiliaryTumors

Home » #HepatobiliaryTumors

Dr. Yinying Lu: Close Relationship Between Gut Microbiota and Hepatobiliary Tumors

Dr. Yinying Lu: Close Relationship Between Gut Microbiota and Hepatobiliary Tumors

Posted by

By Peng Longmei 2024.09.09

Editor’s note: The gut microbiota is one of the most complex microbial communities in the human body and plays a crucial role in both health and disease development. Recently, at…

Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer

Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer

Posted by

By Mourabit Halima 2024.02.16

Editor's Note: In recent years, with the continuous improvement of radiotherapy technology, not only has the effectiveness of tumor reduction been optimized compared to the past, but it has also…

Recent Posts

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Recent Comments

Archives

Categories

Artificial intelligence
Hematology Frontier
Infectious Disease Frontier
International Hepatology
IOncology
Live broadcasting
Uncategorized
UroStream

LinkedIn
Twitter
Mail

Related Media:

Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
Paris, France